TNBC can become resistant to therapy in more than one way, Baylor study finds

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members

Mount Sinai hospital has formed a committee to investigate the ties between Jeffrey Epstein and Eva Dubin a leading doctor at the hospital and founder of the Dubin Breast Center at the Tisch Cancer Institute whose name is featured prominently in the Epstein files.

March 06, 2026

Vol.52 No.09

By Claire Marie Porter and Sara Willa Ernst

Clinical Roundup

Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds

For many women with breast cancer, the treatment that saves their lives also brings fatigue that clings like a heavy coat, loss of muscle mass that turns everyday tasks into obstacles and emotional strain that lingers long after each infusion ends. It’s a season defined not just by survival, but by how well patients are able to live through it.

February 27, 2026

Vol.52 No.08

In Brief

Indiana University receives $5M grant to expand breast cancer diagnosis, care in Kenya

The Indiana University Melvin and Bren Simon Comprehensive Cancer Center has been awarded a $5 million grant from the Pfizer Foundation to expand access to timely breast cancer diagnosis, treatment, and care in Kenya.

February 20, 2026

Vol.52 No.07

Clinical Roundup

Exposure to pathogenic bacteria significantly increased SMOX activity, leading growth and metastasis of breast cancer, JHU-led study finds

Researchers at the Johns Hopkins Kimmel Cancer Center have discovered how certain pathogenic bacteria in gut and breast tissue can promote breast cancer development and progression by hijacking a key metabolic enzyme known as spermine oxidase.

February 20, 2026

Vol.52 No.07

Clinical Roundup

NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer

The NCCN added MammaPrint + BluePrint to the Clinical Practice Guidelines in Oncology for the identification of a subset of hormone receptor positive, HER2-negative early-stage breast cancer patients most likely to benefit from anthracycline-based chemotherapy.

February 06, 2026

Vol.52 No.05

Antibody halts triple-negative breast cancer in preclinical models

Triple-negative breast cancer is one of the most aggressive and treatment-resistant cancers. It grows quickly, spreads early, and lacks hormone receptors that make it treatable with targeted therapies. Even when patients initially respond to treatment, the cancer often returns and is more resistant.

January 30, 2026

Vol.52 No.04

By Hayley Kamin

TNBC can become resistant to therapy in more than one way, Baylor study finds

YOU MAY BE INTERESTED IN

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members

Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds

Indiana University receives $5M grant to expand breast cancer diagnosis, care in Kenya

Exposure to pathogenic bacteria significantly increased SMOX activity, leading growth and metastasis of breast cancer, JHU-led study finds

NCCN updates guidelines recognizing MammaPrint to guide personalized anthracycline use in HR+/HER2- early‑stage breast cancer

Antibody halts triple-negative breast cancer in preclinical models

Renew today!

Subscriber content

Never miss an issue!

Login